GlassScriptPhysician profile
Cheryl Layfield
NPI 1033193479
$9,345.60
in general payments reported to CMS, 2019-2025
33 companies · $3,146 in 2025
The $3,146 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $803 · 2022: $890 · 2023: $2,315 · 2024: $2,192 · 2025: $3,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,652.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,582.47 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Novo Nordisk INC | $642.41 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Gilead Sciences, INC. | $551.03 | 2023-2025 | Epclusa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.66 | 2021-2024 | Jardiance |
| Amgen INC. | $464.54 | 2024-2025 | Krystexxa, Repatha, Uplizna |
| Phathom Pharmaceuticals, INC. | $399.22 | 2024-2025 | Voquezna |
| Abbott Laboratories | $362.07 | 2021 | |
| Lilly USA, LLC | $316.48 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $312.75 | 2023-2025 | |
| Biogen, INC. | $243.11 | 2023 | |
| Kyowa Kirin, INC. | $229.88 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $215.00 | 2025 | Opsumit, Uptravi |
| Abbvie INC. | $206.51 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $205.04 | 2024-2025 | Strensiq |
| Glaxosmithkline, LLC. | $195.09 | 2021-2023 | Trelegy Ellipta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $183.57 | 2025 | Sunosi, Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $171.23 | 2022-2025 | |
| Vertos Medical, INC. | $147.95 | 2023 | Mild Device Kit |
| Xeris Pharmaceuticals, INC. | $135.00 | 2025 | Gvoke Hypopen |
| Verona Pharma, INC. | $125.00 | 2025 | Ohtuvayre |
| Genzyme Corporation | $125.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $124.35 | 2024 | Rexulti |
| Neurelis, INC. | $118.59 | 2023 | Valtoco |
| Sanofi Pasteur INC. | $115.00 | 2022 | |
| Dexcom, INC. | $114.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $105.00 | 2024 | Rezlidhia, Tavalisse |
| Exact Sciences Corporation | $101.69 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $93.44 | 2021 | |
| Shield Therapeutics INC | $82.35 | 2023 | Accrufer |
| Sage Therapeutics, LLC | $72.45 | 2023 | |
| Hologic Sales and Service, LLC | $55.20 | 2025 | Aptima |
| Merck Sharp & Dohme LLC | $48.29 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Medtronic, INC. | $21.23 | 2023 | Inpen Smart Insulin Delivery System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Layfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.